As germs outpace antibiotics, developers hunt for new solutions

Damian Garde The rise of antibiotic-resistant bacteria has become a global scourge, and researchers across academia and industry are taking novel steps to fight back. FierceBiotech ...

As FDA Decision Nears, Amarin CEO Retires And Investors Petition

esilverman Just days before the FDA is expected to decide whether to approve the controversial Vascepa fish oil pill that is sold by Amarin, the little drugmaker has announced ...

Lundbeck stakes out a leading role for itself in late-stage Alzheimer’s R&D

John Carroll While Alzheimer's has long reigned as one of the most challenging fields in R&D, it has also provided some of the most confident projections in the industry. And ...

ADHD experts worry that pharma ads drive too many kids to meds

Tracy Staton Is the huge rise in attention-deficit hyperactivity disorder diagnoses a pharma coup or public-health boon? FiercePharma News

Teva Unveils New Pipeline Assets from the NTE Program

mia.burns  Teva unveils new pipeline assets from the NTE program of 2013 in the 2nd Teva R&D In-Focus Webinar – December 4th @ 8:00am Eastern Time – JERUSALEM–(BUSINESS ...

Bill would fast-track promising antibiotics for FDA approval

Emily Mullin A group of bipartisan members in the House of Representatives introduced a bill late Thursday that aims to combat the growing threat of so-called "superbugs" ...

AstraZeneca, BMS pull Forxiga in Germany in snit over pricing

Eric Palmer AstraZeneca and Bristol-Myers Squibb look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes treatment from the ...

Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments

Eric Palmer It will allow doctors to spot patients who will benefit from those treatments. FiercePharma News

Teva Moves Pipeline Assets from Process to Product

mia.burns By Mia Burns (mia.burns@ubm.com) Teva executives say that developing new pipeline assets through the New Therapeutic Entities, or NTE process is a major element in the company’s ...

AbbVie’s veliparib wows in a breast cancer study

Damian Garde AbbVie's PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response ...

Court Evades US Concern Over False Claims And Side Effect Reports

esilverman Here is a ruling that is nothing but anticlimactic. After a few months of anticipation, a federal appeals court decided not to rule on an issue raised last summer ...

Merck’s allergy pill clears an FDA hurdle, but efficacy questions linger

Damian Garde Merck convinced a panel of FDA advisers that its oral grass allergy immunotherapy could successfully reduce symptoms, but the pill may well face an uphill battle if ...
Page 5 of 6« First...23456
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS